1. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023.
- Author
-
Chung JR, Shirk P, Gaglani M, Mutnal MB, Nowalk MP, Moehling Geffel K, House SL, Curley T, Wernli KJ, Kiniry EL, Martin ET, Vaughn IA, Murugan V, Lim ES, Saade E, Faryar K, Williams OL, Walter EB, Price AM, Barnes JR, DaSilva J, Kondor R, Ellington S, and Flannery B
- Subjects
- Humans, Adult, Male, Female, United States epidemiology, Middle Aged, Young Adult, Adolescent, Aged, Child, Child, Preschool, Infant, Vaccination statistics & numerical data, Aged, 80 and over, Influenza Vaccines immunology, Influenza Vaccines administration & dosage, Influenza, Human prevention & control, Influenza, Human epidemiology, Influenza, Human immunology, Influenza, Human virology, Influenza A Virus, H3N2 Subtype immunology, Influenza A Virus, H3N2 Subtype genetics, Influenza A Virus, H1N1 Subtype immunology, Influenza A Virus, H1N1 Subtype genetics, Outpatients statistics & numerical data, Seasons, Vaccine Efficacy
- Abstract
Background: The 2022-23 US influenza season peaked early in fall 2022., Methods: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design., Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval -9%, 54%); low late-season activity precluded estimation for most subgroups., Conclusions: 2022-23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak., (© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF